论文部分内容阅读
目的 为了尽可能降低急性心肌梗死 (AMI)患者的死亡率 ,为今后的治疗提供依据 ,以进一步提高AMI患者的生存率 ,改善他们的生活质量 ,我们统计了死亡原因并分析死亡率与溶栓治疗之间的关系。方法 收集我院 2 0 0 1年度出院的176例AMI患者病历资料 ,其中男 116例 ,女 6 0例 ,年龄最大 94岁 ,最小 37岁 ,平均年龄 (70 1± 10 5 )岁 ,其中死亡 6 1例。在同一年龄段中根据是否做溶栓治疗分为 2组 :溶栓组与非溶栓组。溶栓治疗组 31例 ,死亡 3例 ;非溶栓治疗组 86例 ,死亡 31例。方法 用SPSS统计学软件包分析 ,数据以均数±标准差 ( x±s)表示 ,用卡方检验和t检验。结果 我院 2 0 0 1年度AMI患者的死亡率为 34 6 6 % ,溶栓治疗率为 18% ,溶栓治疗组的死亡率较未溶栓治疗组显著减少 P <0 0 1,溶栓治疗率低的主要原因是患者发病年龄偏大 ,就诊过迟延误溶栓及溶栓指征掌握偏紧。结果 为了降低AMI的死亡率 ,应提高溶栓治疗的使用率 ,实行溶栓治疗的年龄指征应放宽至 75岁或更高 ,给老年患者提供改善治疗效果的机会 ,以进一步降低AMI患者的死亡率
Objective To reduce the mortality of acute myocardial infarction (AMI) patients as much as possible and provide basis for future treatment to further improve the survival rate of AMI patients and improve their quality of life. We analyzed the causes of death and analyzed the relationship between mortality and thrombolysis The relationship between the treatment. Methods The data of 176 AMI patients discharged in our hospital from 2001 to 2001 were collected, including 116 males and 60 females, the oldest being 94 years old and the youngest being 37 years old, with an average age of 70 1 ± 10 5 years, of whom death 6 1 case. In the same age group according to whether thrombolytic therapy is divided into two groups: thrombolytic group and non-thrombolytic group. Thrombolytic therapy group of 31 patients, 3 patients died; non-thrombolytic therapy group of 86 patients, 31 patients died. Methods SPSS statistical software package analysis, the data as mean ± standard deviation (x ± s) that with chi-square test and t test. Results In 2001, the mortality rate of AMI patients in our hospital was 34 6 6%, and the thrombolytic therapy rate was 18%. The mortality rate of thrombolytic therapy group was significantly lower than that of non-thrombolytic therapy group P <0 01, thrombolysis The main reason for the low treatment rate is the patient’s older age, delayed treatment delay thrombolysis and thrombolytic indications tight grasp. Results In order to reduce the mortality of AMI, we should increase the usage of thrombolytic therapy. The indication of age for thrombolytic therapy should be relaxed to 75 or higher, providing elderly patients with opportunities to improve the therapeutic effect to further reduce the AMI patients mortality rate